최신 재무제표(Form-10K)에 따르면, Aethlon Medical Inc의 총 자산은 $0이며, 순손실입니다.
AEMD의 주요 재무 비율은 무엇인가요?
Aethlon Medical Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Aethlon Medical Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Aethlon Medical Inc 주요 수익원은 Restaurant - In-restaurant Dining이며, 최신 수익 발표에서 수익은 982,349,000입니다. 지역별로는 United States이 Aethlon Medical Inc의 주요 시장이며, 수익은 1,222,501,000입니다.
Aethlon Medical Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Aethlon Medical Inc의 순손실은 $0입니다.
Aethlon Medical Inc에 부채가 있나요?
no, Aethlon Medical Inc의 부채는 0입니다.
Aethlon Medical Inc의 발행 주식은 몇 주인가요?
Aethlon Medical Inc의 총 발행 주식은 0주입니다.
주요 통계
이전 종가
$2.93
시가
$2.93
일일 범위
$2.79 - $3
52주 범위
$2.62 - $137
거래량
35.0K
평균 거래량
99.3K
배당수익률
--
EPS(TTM)
-46.92
시가총액
$7.8M
AEMD란 무엇인가요?
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The firm is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.